Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study.
AndroidAPS
hybrid closed loop
pediatrics
registry
type 1 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
08
2023
accepted:
26
09
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
To compare parameters of glycemic control among three types of hybrid closed loop (HCL) systems in children with T1D (CwD) using population-wide data from the national pediatric diabetes registry ČENDA. CwD aged <19 years treated with Medtronic MiniMed 780G (780G), Tandem t:slim X2 (Control-IQ) or do-it-yourself AndroidAPS (AAPS) systems for >12 months and monitored by CGM >70% of the time were included. HbA1c, times in glycemic ranges, and Glycemia Risk Index (GRI) were used for cross-sectional comparison between the HCL systems. Data from 512 CwD were analyzed. 780G, Control-IQ and AAPS were used by 217 (42.4%), 211 (41.2%), and 84 (16.4%) CwD, respectively. The lowest HbA1c value was observed in the AAPS group (44 mmol/mol; IQR 8.0, p<0.0001 vs any other group), followed by Control-IQ and 780G groups (48 (IQR 11) and 52 (IQR 10) mmol/mol, respectively). All of the systems met the recommended criteria for time in range (78% in AAPS, 76% in 780G, and 75% in Control-IQ users). CwD using AAPS spent significantly more time in hypoglycemia (5% vs 2% in 780G and 3% in Control-IQ) and scored the highest GRI (32, IQR 17). The lowest GRI (27, IQR 15) was seen in 780G users. Although all HCL systems proved effective in maintaining recommended long-term glycemic control, we observed differences that illustrate strengths and weaknesses of particular systems. Our findings could help in individualizing the choice of HCL systems.
Identifiants
pubmed: 37908748
doi: 10.3389/fendo.2023.1283181
pmc: PMC10613700
doi:
Substances chimiques
Glycated Hemoglobin
0
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283181Informations de copyright
Copyright © 2023 Santova, Plachy, Neuman, Pavlikova, Petruzelkova, Konecna, Venhacova, Skvor, Pomahacova, Neumann, Vosahlo, Strnadel, Kocourkova, Obermannova, Pruhova, Cinek and Sumnik.
Déclaration de conflit d'intérêts
ZS, LP and SP reported speakers’ honoraria from Medtronic, Abbott and A-Import. VN reported speakers’ honoraria from Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
Diabetes Technol Ther. 2021 Sep;23(9):601-608
pubmed: 33784196
Diabetes Care. 2021 Apr;44(4):969-975
pubmed: 33579715
JMIR Mhealth Uhealth. 2019 Jul 30;7(7):e14087
pubmed: 31364599
N Engl J Med. 2020 Aug 27;383(9):836-845
pubmed: 32846062
Diabetes Technol Ther. 2021 Feb;23(2):120-127
pubmed: 32846114
Lancet Diabetes Endocrinol. 2022 Oct;10(10):720-731
pubmed: 36058207
Lancet Diabetes Endocrinol. 2022 Jan;10(1):58-74
pubmed: 34785000
Diabetes Obes Metab. 2022 Jul;24(7):1370-1379
pubmed: 35403792
Pediatr Diabetes. 2021 May;22(3):439-447
pubmed: 33533545
Pediatr Diabetes. 2022 Dec;23(8):1496-1511
pubmed: 36537520
Diabetes Technol Ther. 2023 Jun;25(6):404-413
pubmed: 36763343
Acta Diabetol. 2022 Jul;59(7):959-964
pubmed: 35451679
Diabetol Metab Syndr. 2016 Jul 29;8:53
pubmed: 27478509
Pediatr Diabetes. 2020 Feb;21(1):77-87
pubmed: 31605416
Diabetes Technol Ther. 2022 Feb;24(2):113-119
pubmed: 34524003
Diabetologia. 2021 May;64(5):1007-1015
pubmed: 33550442
N Engl J Med. 2023 Mar 16;388(11):991-1001
pubmed: 36920756
J Diabetes Sci Technol. 2023 Sep;17(5):1226-1242
pubmed: 35348391
Horm Res Paediatr. 2023 Apr 26;:
pubmed: 37100041
Diabetes Technol Ther. 2022 Mar;24(3):178-189
pubmed: 34694909
Pediatr Diabetes. 2021 Jun;22(4):594-604
pubmed: 33576551
PLoS One. 2021 Apr 5;16(4):e0248965
pubmed: 33819289
Front Endocrinol (Lausanne). 2023 Jan 26;14:1099024
pubmed: 36777356
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185